Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin and Skin Structure Infection

Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin and Skin Structure Infection

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Apr 2018

At a glance

  • Drugs Ceftaroline fosamil (Primary) ; Aztreonam; Vancomycin
  • Indications Skin and soft tissue infections
  • Focus Registrational; Therapeutic Use
  • Acronyms CANVAS-I; cSSSI
  • Sponsors Cerexa; Forest Laboratories
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 24 Apr 2018 Results assessing comparison of safety profile of two regimens of ceftaroline fosamil by using data from six phase III studies (COVERS, CANVAS 1, CANVAS 2, FOCUS 1, FOCUS 2, and asian CAP) presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases.
    • 12 Apr 2016 Results from CANVAS-1, CANVAS 2, COVERS, FOCUS 1, FOCUS 2 and Asia CAP trials (n=4055) presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top